In established atherosclerosis, P2Y12 inhibitor vs. aspirin monotherapy reduces MI but not stroke or mortality

Ann Intern Med. 2020 Sep 15;173(6):JC26. doi: 10.7326/ACPJ202009150-026.

Abstract

Chiarito M, Sanz-Sánchez J, Cannata F, et al. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet. 2020;395;1487-95. 32386592.

Publication types

  • Comment

MeSH terms

  • Aspirin / therapeutic use
  • Atherosclerosis* / drug therapy
  • Atherosclerosis* / prevention & control
  • Hemorrhage
  • Humans
  • Patients
  • Percutaneous Coronary Intervention*
  • Platelet Aggregation Inhibitors / adverse effects
  • Purinergic P2Y Receptor Antagonists / therapeutic use
  • Secondary Prevention
  • Stroke* / prevention & control

Substances

  • Platelet Aggregation Inhibitors
  • Purinergic P2Y Receptor Antagonists
  • Aspirin